- Home
- LUCY vs CVKD Comparison
LUCY vs CVKD Comparison
Compare LUCY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- CVKD
- Stock Information
- Founded
- LUCY 2017
- CVKD 2022
- Country
- LUCY United States
- CVKD United States
- Employees
- LUCY N/A
- CVKD N/A
- Industry
- LUCY Ophthalmic Goods
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- LUCY Health Care
- CVKD Health Care
- Exchange
- LUCY Nasdaq
- CVKD Nasdaq
- Market Cap
- LUCY 18.5M
- CVKD 17.1M
- IPO Year
- LUCY 2022
- CVKD 2023
- Fundamental
- Price
- LUCY $6.90
- CVKD $14.45
- Analyst Decision
- LUCY Strong Buy
- CVKD Strong Buy
- Analyst Count
- LUCY 1
- CVKD 2
- Target Price
- LUCY $20.00
- CVKD $52.50
- AVG Volume (30 Days)
- LUCY 104.1K
- CVKD 59.6K
- Earning Date
- LUCY 11-12-2024
- CVKD 11-08-2024
- Dividend Yield
- LUCY N/A
- CVKD N/A
- EPS Growth
- LUCY N/A
- CVKD N/A
- EPS
- LUCY N/A
- CVKD N/A
- Revenue
- LUCY $1,529,782.00
- CVKD N/A
- Revenue This Year
- LUCY $245.17
- CVKD N/A
- Revenue Next Year
- LUCY $258.97
- CVKD N/A
- P/E Ratio
- LUCY N/A
- CVKD N/A
- Revenue Growth
- LUCY 186.54
- CVKD N/A
- 52 Week Low
- LUCY $3.26
- CVKD $5.40
- 52 Week High
- LUCY $27.20
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- LUCY 44.95
- CVKD 56.80
- Support Level
- LUCY $6.33
- CVKD $11.19
- Resistance Level
- LUCY $6.89
- CVKD $17.95
- Average True Range (ATR)
- LUCY 0.59
- CVKD 1.37
- MACD
- LUCY -0.27
- CVKD 0.10
- Stochastic Oscillator
- LUCY 14.46
- CVKD 49.64
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.